Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6249
Provisional Schedule
- Expected publication:
- 04 March 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Janssen-Cilag (daratumumab, bortezomib)
- Others
- Department of Health and Social Care
- Heath Technology Wales
- NHS England
- Patient carer groups
- Blood Cancer UK
- Myeloma UK
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- UK Myeloma Society
- Comparator companies
- •Advanz Pharma (lenalidomide) No CAU, Not participating
- •Amarox (lenalidomide) No CAU, Not participating
- •Aspire (bortezomib) No CAU, Not participating
- •Aurobindo Pharma (bortezomib) No CAU, Not participating
- •Biocon Pharma (lenalidomide) No CAU, Not participating
- •Biotech Pharma (bortezomib) No CAU, Not participating
- •Bristol Myers Squibb (lenalidomide, thalidomide) CAU Received, participating
- •Dr Reddy’s Laboratories (bortezomib) No CAU, Not participating
- •Grindeks Kalceks UK (lenalidomide) No CAU, Not participating
- •MSN laboratories Europe (bortezomib) No CAU, Not participating
- •Mylan (lenalidomide) No CAU, Not participating
- •Pfizer (bortezomib)- CAU Received- Participating
- •Piramal Critical Care (lenalidomide) No CAU, Not participating
- •Ranbaxy UK (bortezomib, lenalidomide) No CAU, Not participating
- •Sandoz (bortezomib, lenalidomide) No CAU, Not participating
- •Teva UK (lenalidomide) No CAU, Not participating
- •Thornton & Ross (bortezomib, lenalidomide) No CAU, Not participating
- •Tillomed Laboratories (bortezomib) No CAU, Not participating
- •Zentiva (thalidomide) – No CAU, Not participating
- General commentators
- Adaptive Biotech
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 December 2025 | Committee meeting: 1 |
| 13 May 2025 | Invitation to participate |
| 17 March 2025 - 14 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6249 |
| 17 March 2025 | In progress. Scoping commencing |
| 19 January 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual